Skip to content

HAKA: Routine Follow-Up at 1 Year After Hip- or Knee Arthroplasty: Wasting Resources or Appropriate Healthcare?

Cost-effectiveness of Routine Follow-up at One Year After Total Hip and Knee Arthroplasty Compared to Check-up on Demand: a Multicenter Hybrid Stepped-wedge Cluster De-implementation Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06971757
Acronym
HAKA 1year FU
Enrollment
1000
Registered
2025-05-14
Start date
2025-07-01
Completion date
2029-12-31
Last updated
2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Arthroplasty, Total, Knee Arthroplasty, Total

Keywords

total hip arthroplasty, total knee arthroplasty, follow-up, PROMIS physical function, healthcare consumption

Brief summary

After undergoing total hip or total knee arthroplasty, current guidelines recommend routine follow-up with an X-ray within 3 months and again at 1 year. Follow-up at 5 years (for hip arthroplasties) or every 5 years (for knee arthroplasties) is also considered worthwhile according to the guideline. However, these follow-up appointments require considerable time from patients, caregivers, and healthcare professionals, and it is unclear whether they are truly beneficial. It is possible that a single follow-up within 3 months is sufficient. This could potentially prevent over 100,000 unnecessary hospital visits per year, resulting in significant cost savings. If patients or healthcare providers have concerns, they can always request an additional follow-up. The HAKA trial consists of three different work packages (WPs). This trial (WP1) investigates the 1-year follow-up, WP2 examines the 10-year follow-up, and WP3 is a qualitative study exploring the experiences and perceptions of patients and healthcare professionals. The aim of the HAKA trial is to safely reduce routine follow-up appointments after total hip or knee arthroplasty and to revise current clinical guidelines accordingly.

Interventions

Standard follow-up care with scheduled X-ray and clinical visit at 3 months and 1 year after surgery.

OTHERCheck-Up on Demand (COD)

Follow-up care with scheduled X-ray and clinical visit at 3 months and only at 1 year if requested.

Sponsors

Reinier Haga Orthopedisch Centrum
CollaboratorOTHER
Tergooi MC
CollaboratorUNKNOWN
JointResearch
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

This is a hybrid effectiveness (de-)implementation trial type II, with a stepped-wedge cluster trial design. A total of 10 hospitals will transition from a period with RFU to a period with COD, with a wash-out period (transition) of 2 months. The aim is to gradually de-implement RFU, with all centers eventually using COD as the standard of care.

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Painful and disabled hip or knee joint resulting from osteoarthritis * Scheduled for primary THA or TKA surgery * Age 50 years or older at the time of THA or TKA * Capable and willing to complete questionnaires * Proficient in Dutch or English * Willing to provide informed consent

Exclusion criteria

* Other indication for surgery than osteoarthritis * Scheduled for hip or knee revision arthroplasty, except a conversion from unicompartmental knee arthroplasty to TKA or from hip hemiarthroplasty/resurfacing to THA * Already participating in this study due to a previous hip or knee surgery

Design outcomes

Primary

MeasureTime frameDescription
PROMIS Physical FunctionAssessed before surgery and at 3, 12, 15, 18, and 24 months after surgery.Patient-reported physical functioning will be assessed using the PROMIS® Physical Function Version 1.0, Short Form 10a. The short form consists of 10 items and is expressed by raw summed score ranging from 10 to 50, which can be converted to a T-score and SE. The T-score is a standardized score with a mean of 50 and a SD of 10. Higher T-scores indicate better physical functioning.
Number of clinical visits and X-raysFrom surgery until 24 months after surgery.Assesses healthcare consumption based on the number of postoperative outpatient clinical visits and X-ray assessments.

Secondary

MeasureTime frameDescription
Number of surgical interventionsFrom surgery until 24 months after surgery.The total number of surgical re-interventions per patient related to the index procedure will be recorded.
Type of Surgical InterventionsFrom surgery until 24 months after surgeryTypes of surgical re-interventions will be recorded and categorized (e.g., DAIR, partial component exchange, full revision, irrigation and debridement without component retention).
Number of complicationsFrom surgery until 24 months after surgery.The total number of post-operative complications per patient will be recorded.
Numeric Pain Rating Scale (NPRS)Assessed before surgery and at 3, 12, 15, 18, and 24 months after surgery.Patient-reported pain intensity, measured using a numeric scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores reflect more severe pain.
EQ-5D-5LAssessed before surgery and at 3, 12, 15, 18, and 24 months after surgery.Health-related quality of life is measured using the EQ-5D-5L questionnaire. The EQ-5D-5L index score ranges from -0.594 to 1.000, where 1.000 indicates full health, 0 represents death, and negative values represent health states worse than death. Higher scores indicate better health status.
Costs related to THA or TKA follow-upAssessed at 15, 18, and 24 months after surgery.Includes costs from electronic health records and additional patient questionnaires, covering hospital and non-hospital care.
Type of ComplicationsFrom surgery until 24 months after surgery.Complication types will be recorded and categorized (e.g., infection, periprosthetic fracture, loosening, malalignment, dislocation, prosthetic wear).

Countries

Netherlands

Contacts

Primary ContactLidy A.C. Roubos, MSc.
L.A.C.Roubos@olvg.nl+31 20 599 3653

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026